Strategies for design of non peptide CCK1R agonist/antagonist ligands.
This review mainly covers last five year literature on CCK1R agonists and antagonists. These CCK1R ligands have been found following the two usual and complementary strategies for drug discovery: rational design based on structure activity relationships on the CCK-7 and CCK-4 peptide sequences of the endogenous ligands and random screening of diverse compounds, followed by hit optimization. The first group includes: chimeric bifunctional opioid/CCK peptides, designed as opioid agonists with balanced CCK1R/CCK2R antagonist activity for the treatment of neuropathic pain, antagonist and agonist dipeptoids, and 1,3-dioxoperhydropyrido[1,2-c]pyrimidine- and anthranilic acid-based antagonists. Among the ligands derived from random screening, a few new 1,4-benzodiazepine-, 1,5-benzodiazepine-, and five member ring heterocycle-based CCK1R ligands have been reported. Finally, taking into account the importance of receptor mapping studies for ligand optimization and future precise de novo receptor structure-based design of new selective and more effective ligands, the most significant conclusions of these studies have also been reviewed.
García-López
M Teresa
MT
Instituto de Química Médica (CSIC), Juan de la Cierva 3, E-28006 Madrid, Spain.
González-Muñiz
Rosario
R
Martín-Martínez
Mercedes
M
Herranz
Rosario
R
D000818:Animals; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008024:Ligands; D010455:Peptides / Q000378:metabolism; D011949:Receptors, Cholecystokinin / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000378:metabolism
D008024:Ligands; D010455:Peptides; D011949:Receptors, Cholecystokinin